Page 113

196. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. 2000. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol.; 102: 98-106..

197. Sharief MK, Hentges R. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med.; 325: 467-72..

198. Silver NC, Barker GJ, Miller DH. 1999. Standardization of magnetization transfer imaging for multicenter studies. Neurology.; 53: S33-9..

199. Simon JH. 2000. The contribution of spinal cord MRI to the diagnosis and differential diagnosis of multiple sclerosis. J Neurol Sci.; 172: S32-5..

200. Simon JH. 1999. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol.; 98: 7-15..

201. Sorensen PS. 1999. Biological markers in body fluids for activity and progression in multiple sclerosis. Mult Scler.; 5: 287-90..

202. Sorensen TL, Tani M, Jensen J, et al. 1999. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest.; 103: 807-15..

203. Sriram S, Stratton CW, Yao S, et al. 1999. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol.; 46: 6-14..

204. Stalder AK, Carson MJ, Pagenstecher A, et al. 1998. Late-onset chronic inflammatory e cephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am J Pathol.; 153: 767-83..

205. Steinman L. 2000. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. J Autoimmun.; 14: 278-82..

206. Steinman L, Oldstone MB. 1997. More mayhem from molecular mimics. Nat Med.; 3: 1321-2..

207. Stinissen P, Raus J, Zhang J. 1997. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol.; 17: 33-75..

208. Streit WJ. 2000. Microglial response to brain injury: a brief synopsis. Toxicol Pathol.; 28: 28-30..

209. Thompson AJ, Montalban X, Barkhof F, et al. 2000. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol.; 47: 831-5..

210. Thompson EJ. 1995. Cerebrospinal fluid. J Neurol Neurosurg Psychiatry.; 59: 349-57..

211. Townsend JJ, Baringer JR. 1979. Morphology of central nervous system disease in immun suppressed mice after peripheral herpes simplex virus inoculation. Trigeminal root entry zone. Lab Invest.; 40: 178-82..

212. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. New Engl J Med.; 338: 278-285..

213. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. 1999. Neurodegeneration in multiple sclerosis: relationship to neurological disability. The Neuroscientist.; 5: 48-57..

214. Trowsdale J. Molecular genetics of HLA class I and class II regions. Browning M, McMichael A, eds. HLA and MHC: Genes, Molecules and Function .em>. Oxford. BIOS Scientific Publishers Limited. 1996.

215. Van der Neut R. 1997. Targeted gene disruption: applications in neurobiology. J Neurosci Methods.; 71: 19-27..

216. Vandevyver C, Mertens N, van den Elsen P, Medaer R, Raus J, Zhang J. 1995. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: restricted T cell receptor V gene rearrangements and CDR3 sequence. Eur J Immunol.; 25: 958-68..

217. Wallstrom E, Khademi M, Andersson M, Weissert R, Linington C, Olsson T. 1998. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur J Immunol.; 28: 3329-35..

218. Waxman SG. 1982. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med.; 306: 1529-33..



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement